Technical Analysis for IONS - Ionis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 58.03 0.75% 0.43
IONS closed up 0.75 percent on Friday, January 18, 2019, on 1.3 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical IONS trend table...

Date Alert Name Type % Chg
Jan 18 New Uptrend Bullish 0.00%
Jan 18 Pocket Pivot Bullish Swing Setup 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Overbought Stochastic Strength 0.75%
Jan 16 Stochastic Sell Signal Bearish 1.49%
Jan 16 Overbought Stochastic Strength 1.49%
Jan 15 180 Bullish Setup Bullish Swing Setup -0.39%
Jan 15 Overbought Stochastic Strength -0.39%
Jan 14 Stochastic Sell Signal Bearish 2.91%
Jan 14 Outside Day Range Expansion 2.91%

Older signals for IONS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. It markets KYNAMRO for the treatment of homozygous familial hypercholesterolemia. The company's drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug for the treatment of patients with various forms of TTR amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis; and nusinersen, a drug for the treatment of infants and children with spinal muscular atrophy. It is also developing Custirsen, which is in two Phase III studies to treat cancer; and Plazomicin that is Phase III study for the treatment of severe bacterial infection. In addition, the company is developing products, which are Phase II clinical trials include IONIS-DMPK-2.5Rx for myotonic dystrophy type 1; IONIS-HTTR for huntington's disease; ATL1103 for acromegaly; IONIS-FXIRx (BAY 2306001) for clotting disorders; IONIS-APO(a)-LRx for high Lp; IONIS-ANGPTL3-LRx for mixed dyslipidemias; Apatorsen (OGX-427) and IONIS-STAT3-2.5Rx (AZD9150) for cancers; EXC 001 (PF-06473871) for scarring; ATL1102 for multiple sclerosis; and RG-101 for hepatitis C virus infection, as well as products for the treatment of diabetes and obesity. Further, its products in Phase I clinical include IONIS-GCCRRx for cushing's syndrome; IONIS-PKKRx for hereditary angioedema; RG-012 for alport syndrome; IONIS-AR-2.5Rx (AZD5312) for prostate cancer; IONIS-HBVRx for hepatitis B virus infection; IONIS-GSK4-LRx for ocular disease; and IONIS-DGAT2Rx for nonalcoholic steatohepatitis. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Is IONS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 59.81
52 Week Low 39.07
Average Volume 959,203
200-Day Moving Average 48.0824
50-Day Moving Average 54.2412
20-Day Moving Average 54.6795
10-Day Moving Average 57.382
Average True Range 2.1421
ADX 25.32
+DI 17.6161
-DI 9.3529
Chandelier Exit (Long, 3 ATRs ) 52.3937
Chandelier Exit (Short, 3 ATRs ) 54.6963
Upper Bollinger Band 60.7751
Lower Bollinger Band 48.5839
Percent B (%b) 0.77
BandWidth 22.295742
MACD Line 1.3297
MACD Signal Line 1.0276
MACD Histogram 0.3021
Fundamentals Value
Market Cap 7.21 Billion
Num Shares 124 Million
EPS 0.21
Price-to-Earnings (P/E) Ratio 276.33
Price-to-Sales 13.91
Price-to-Book 31.29
PEG Ratio -7.79
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 60.57
Resistance 3 (R3) 60.32 59.22 60.14
Resistance 2 (R2) 59.22 58.58 59.35 60.00
Resistance 1 (R1) 58.63 58.18 58.93 58.88 59.86
Pivot Point 57.53 57.53 57.68 57.66 57.53
Support 1 (S1) 56.94 56.89 57.24 57.19 56.20
Support 2 (S2) 55.84 56.49 55.97 56.06
Support 3 (S3) 55.25 55.84 55.92
Support 4 (S4) 55.50